STAT+: In race to make gene therapy for age-related blindness, 4D Molecular announces positive results
A long-running race to develop a gene therapy for the most common cause of age-related…
Category: drug development
Vance on ACA, diagnosing myopia, and fallout from a retracted study
In a story today from STAT’s Anil Oza, I learned that researcher and physician Alex…
Bernie Sanders keeps the heat on Novo’s high prices
Want to stay on top of the science and politics driving biotech today? Sign up to get…
FDA formalizes protocol for international cancer trials
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The essential biotech updates of the day
Morning! Today, we talk about bioethics, catch up on some reports from ESMO, and wonder aloud…
STAT+: Checkpoint inhibitor staves off disease progression in anal cancer trial
BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients…
The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
Can GLP-1 drugs help with type 1 diabetes?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more
For more cancer coverage, sign up for STAT’s pop-up newsletter focused on this weekend’s European…
Moderna cuts spending, and Sarepta’s ‘curse’ on Califf
Good morning. If you’re following the European Society for Medical Oncology meeting that starts tomorrow,…
STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion
Moderna said Thursday it would cut its annual spending on research and development by 23%,…
Eli Lilly releases new data on weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Five biotech news stories you need to read today
Morning! Today, we’ll keep riding the bispecific wave, and tell you what Verily and FDA…
Terns’ GLP-1 pill leads to weight loss in early study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Relay discloses encouraging results for experimental breast cancer treatment
Relay Therapeutics disclosed encouraging results for its key breast cancer drug and plans to advance…
STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its…
Opinion: How Pfizer ended up passing on my GLP-1 work back in the early ’90s
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and…
STAT+: U.K. charities give $36 million to start new drugs for childhood tumors
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and…
Lilly has more positive data on its weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target
Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial…
BioMarin’s big day today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial
A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal,…
A STAT Investigation: Embedded Bias
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a…
Genentech is shedding even more employees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Hims takes a blow from Lilly’s vial news
Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+…
Pfizer and Lilly want to sell you drugs directly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A Galapagos investor signals impatience with its turnaround efforts
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi
LONDON — Leqembi, the Alzheimer’s treatment from Eisai and Biogen, has hit another roadblock reaching…
STAT+: Gene therapy pioneer Jim Wilson believes he can commercialize rare-disease drugs in a tough climate
If you’d told Jim Wilson three years ago that he’d be stepping down as director…
Opinion: In drug development, diversity must be extended to preclinical research
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on,…
STAT+: What to know about Alnylam’s upcoming readout on its heart drug
Next week, the biopharma world will see eagerly awaited results from a trial that could…
STAT+: AI drug firm Recursion moves from survival to industry domination
SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at…
Is pharma still fearful of the Inflation Reduction Act?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The business of CRISPR’d medicine: Not great
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
We have mpox vaccines now. But how will they be distributed?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Syros shares battered after it stops leukemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Acelyrin announces layoffs, strategy shift after late-stage trial results for anti-inflammatory drug
Acelyrin, a California biotech focused on immunology and inflammatory disease, announced Tuesday that its experimental…
Atai advances oral psychedelic in depression
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A tough week for MDMA-assisted psychotherapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
FDA approves EpiPen alternative, a nasal spray for anaphylaxis
On Friday, the Food and Drug Administration approved the first needle-free treatment for adults and…
Why did Novo pull heart failure paperwork for Wegovy?
Hey, humans. Today, we talk about the decades-long pursuit to get MDMA approved as a…
Listen: VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a…
STAT+: A strong start for Madrigal’s MASH drug launch
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Sarepta CEO: We’re ‘pretty brilliant’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A new drug for glioma means a windfall for Agios
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The exclusive biotech stories you need to read
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: ‘Jerking families around’: Canceled Roche rare disease trial devastates parents, angers researchers
Roche, the Swiss pharmaceutical giant, earlier this year abruptly cancelled an international clinical trial of…
FDA ad comm favors Zevra’s Niemann-Pick drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Moderna is still in a Covid hangover
Want to stay on top of the science and politics driving biotech today? Sign up to get…